The actor is leading a campaign focused on joint pain.
Zimmer Biomet Holdings
Some marketing campaigns just write themselves.
Zimmer Biomet Holdings launched a new educational campaign targeting people living with joint pain.1 The campaign is headlined by Arnold Schwarzenegger and is appropriately named “You’ll Be Back.” In the launch video, the action star urges people to share their stories of living with joint pain.
Schwarzenegger is also the chief mobility officer at Zimmer.
In a press release, he said, “Throughout my decades-long fitness crusade, I have seen the power in building community. You'll Be Back aims to bring together people who are struggling with their mobility and inspire change and action. People want to be successful, but fear, uncertainty and lack of vision can get in their way. Whether you want to play on the floor with your grandkids like I do, get up out of the chair pain-free or train for your next 5K race, life is too short to let pain stop you from doing what you love! I want to hear from you what is holding you back."
In the same press release, Zimmer Biomet president and chief executive officer Ivan Tornos added, “There are millions of people living in pain and very few are doing anything about it and instead living in pain for years before seeking treatment. No one is better positioned to ignite this movement to motivate people to terminate their pain more than the Terminator himself. The rapid innovation we are driving in our industry has made it easier and faster to recover from joint replacement surgeries. Now is the time to empower patients to have a voice and a choice in their health journey."
Zimmer Biomet also recently announced several changes to its board of directors.2 Christopher Begley is retiring as chairman of the board at the end of May, at which point Tornos will take his place. Michael Farrell will also become lead independent director at that time.
In a press release, Tornos said, “Chris has been a tremendous advisor to Zimmer Biomet since joining the Board in 2012. His vision, thoughtful counsel, and dedication to the Company have been instrumental in positioning Zimmer Biomet as a MedTech leader and innovator. On behalf of the entire Board of Directors and Leadership Team, I want to extend my deep gratitude to Chris for his exemplary leadership and service as a member of Zimmer Biomet's Board. We have all benefited immensely from Chris's guidance, leadership and mentorship as Board Chair."
He continued, “We are honored to have Mick serve as our Lead Independent Director. He is a respected and accomplished business leader who brings strong integrity, a collaborative approach, and a valuable strategic perspective to our Board. I look forward to working with him in his new role."
Begley, in the same press release, added, “Ivan has demonstrated bold leadership during his tenure as President and CEO, and prior to that as Chief Operating Officer, at Zimmer Biomet. I and the entire Board of Directors are excited to see how he continues to drive even stronger value for patients, shareholders, physicians and customers in his expanded role as Chairman of the Board."
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Social Media's Influence on Young Women's Reproductive Decisions
February 20th 2025In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.